Profile data is unavailable for this security.
About the company
NanoViricides, Inc. is a clinical-stage company. The Company is engaged in developing a class of drugs that it calls nanoviricides, using a platform technology based on the application of nanomedicine technologies to the complex issues of viral diseases. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that has demonstrated activity in lethal lung infection animal model studies of Coronavirus (COVID), Respiratory Syncytial Virus, Influenza, Orthopoxvirus model for Smallpox and MPox, and even in a humanized mice model for Measles. It is focused on advancing Phase II clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles rash. Its NV-CoV-2 and NV-CoV-2-R are drug candidates for the treatment of COVID. Its portfolio also includes NV-HIV-1, a novel mechanism Anti-HIV Drug Candidate. Its other drug candidates include treatment for viral infections, including Dengue viruses, Ebola viruses, among others.
- Revenue in USD (TTM)0.00
- Net income in USD-8.32m
- Incorporated2023
- Employees7.00
- LocationNanoViricides, Inc1 Controls DriveSHELTON 06484United StatesUSA
- Phone+1 (203) 937-6137
- Fax+1 (302) 655-5049
- Websitehttps://www.nanoviricides.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Regentis Biomaterials Ltd | 0.00 | -13.65m | 20.53m | -- | -- | 4.33 | -- | -- | -24.08 | -24.08 | 0.00 | 0.9159 | 0.00 | -- | -- | -- | -336.99 | -188.09 | -- | -- | -- | -- | -- | -- | -- | -1.02 | 0.2015 | -- | -- | -- | -360.91 | -- | -- | -- |
| Finch Therapeutics Group Inc | 0.00 | -14.17m | 21.28m | 18.00 | -- | 1.50 | -- | -- | -8.82 | -8.82 | 0.00 | 8.86 | 0.00 | -- | -- | -- | -25.20 | -- | -28.80 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -87.57 | -- | 34.80 | -- | -- | -- |
| Aspira Women's Health Inc | 9.34m | -10.80m | 21.63m | 66.00 | -- | -- | -- | 2.32 | -0.3782 | -0.3782 | 0.3387 | -0.1018 | 1.55 | 11.79 | 7.26 | 141,469.70 | -179.16 | -116.24 | -903.68 | -168.65 | 63.90 | 50.98 | -115.66 | -287.59 | 1.32 | -189.81 | -- | -- | 0.3059 | 15.14 | 21.55 | -- | -22.58 | -- |
| Cue Biopharma Inc | 7.10m | -37.68m | 22.05m | 41.00 | -- | 1.64 | -- | 3.11 | -0.4553 | -0.4553 | 0.0823 | 0.1703 | 0.1857 | -- | 4.01 | 173,170.70 | -98.58 | -60.20 | -170.74 | -73.56 | -- | -- | -530.75 | -683.99 | -- | -- | 0.1107 | -- | 69.16 | 21.84 | 19.83 | -- | 7.32 | -- |
| Fibrobiologics Inc | 0.00 | -18.65m | 22.21m | 15.00 | -- | 3.55 | -- | -- | -0.444 | -0.444 | 0.00 | 0.0925 | 0.00 | -- | -- | 0.00 | -143.08 | -- | -322.07 | -- | -- | -- | -- | -- | -- | -12.08 | 0.00 | -- | -- | -- | -67.06 | -- | -- | -- |
| Apollomics Inc | 8.50m | -31.19m | 22.30m | 13.00 | -- | -- | -- | 2.62 | -26.61 | -26.61 | 8.01 | -3.99 | 0.3721 | -- | -- | 653,846.10 | -136.51 | -- | -276.35 | -- | -- | -- | -366.92 | -- | -- | -- | -- | -- | -- | -- | 68.80 | -- | -- | -- |
| Neuphoria Therapeutics Inc | 15.00m | -5.66m | 22.37m | 7.00 | -- | 0.7514 | -- | 1.49 | -2.12 | -2.12 | 5.77 | 5.52 | 0.5478 | -- | 26.19 | 2,142,857.00 | -20.68 | -35.39 | -22.63 | -39.01 | -- | -- | -37.76 | -375.66 | -- | -4.22 | 0.0011 | -- | -- | 246.65 | 97.61 | -- | -- | -- |
| NanoViricides, Inc | 0.00 | -8.32m | 22.67m | 7.00 | -- | 2.05 | -- | -- | -0.4842 | -0.4842 | 0.00 | 0.5127 | 0.00 | -- | -- | 0.00 | -69.79 | -43.34 | -77.53 | -45.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -14.14 | -- | 45.82 | -- |
| LAMY | 0.00 | 106.70k | 23.10m | -- | 24.05 | -- | 190.26 | -- | 0.0137 | 0.0137 | 0.00 | -0.0045 | 0.00 | -- | -- | -- | 763.23 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -67.39 | -- | 299.15 | -- | -- | -- |
| Vistagen Therapeutics Inc | 805.00k | -67.05m | 23.22m | 59.00 | -- | 0.456 | -- | 28.84 | -1.90 | -1.90 | 0.0228 | 1.29 | 0.0102 | -- | -- | 14,375.00 | -85.21 | -55.19 | -99.91 | -59.56 | -- | -- | -8,328.70 | -5,842.62 | -- | -- | 0.0074 | -- | -54.32 | -- | -75.12 | -- | -- | -- |
| Linike Medical Group Ltd | 0.00 | -306.90k | 23.41m | -- | -- | -- | -- | -- | -0.1102 | -0.1102 | 0.00 | -0.153 | 0.00 | -- | -- | -- | -278.62 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -651.26 | -- | -- | -- |
| Exicure Inc | 0.00 | -9.23m | 23.84m | 8.00 | -- | 3.44 | -- | -- | -3.07 | -3.07 | 0.00 | 1.09 | 0.00 | -- | -- | 0.00 | -71.27 | -44.45 | -94.78 | -60.08 | -- | -- | -- | -259.52 | -- | -- | 0.00 | -- | -- | -17.34 | 42.65 | -- | -- | -- |
| Skye Bioscience Inc | 0.00 | -51.23m | 23.88m | -- | -- | 0.703 | -- | -- | -1.29 | -1.29 | 0.00 | 1.06 | 0.00 | -- | -- | -- | -83.39 | -139.20 | -94.11 | -262.81 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 29.43 | -- | -- | -- |
| Marker Therapeutics Inc | 4.69m | -14.30m | 24.68m | 5.00 | -- | 1.34 | -- | 5.26 | -1.23 | -1.23 | 0.3683 | 1.10 | 0.2876 | -- | 3.90 | 938,996.00 | -87.60 | -57.72 | -110.67 | -69.11 | -- | -- | -304.54 | -761.28 | -- | -- | 0.00 | -- | 99.06 | 98.63 | 23.60 | -- | -- | -- |
| Senti Biosciences Inc | 0.00 | -47.58m | 24.82m | 34.00 | -- | 3.06 | -- | -- | -2.80 | -2.80 | 0.00 | 0.3089 | 0.00 | -- | -- | 0.00 | -86.19 | -50.97 | -106.55 | -57.59 | -- | -- | -- | -2,565.78 | -- | -- | 0.00 | -- | -100.00 | -- | 36.71 | -- | -58.03 | -- |
Data as of Feb 27 2026. Currency figures normalised to NanoViricides, Inc's reporting currency: US Dollar USD
13.01%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 31 Dec 2025 | 1.37m | 6.34% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 511.48k | 2.37% |
| Geode Capital Management LLCas of 31 Dec 2025 | 174.37k | 0.81% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 173.40k | 0.80% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 158.75k | 0.74% |
| Jane Street Capital LLCas of 31 Dec 2025 | 124.07k | 0.58% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 90.39k | 0.42% |
| Citadel Securities LLCas of 31 Dec 2025 | 79.92k | 0.37% |
| Miller Financial Services LLCas of 31 Dec 2025 | 72.00k | 0.33% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 54.21k | 0.25% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
